Sobi inleder nytt samarbete inom sepsis

Särläkemedelsbolaget Sobi inleder ett nytt forskningssamarbete och en klinisk studie kring en potentiell behandling vid sepsis.

Svensk obesitaskandidat visade lovande resultat – ”Kan få stor betydelse”

Tabletten ska främja viktminskning utan att påverka aptit eller muskelmassa. Resultaten är lovande, enligt en klinisk fas I-studie från Karolinska institutet oc...

Studie: Upptäckt om tarmceller ger hopp om att bromsa Crohns sjukdom

Forskare vid Göteborgs universitet har upptäckt ett nytt sätt att angripa Crohns sjukdom. Det handlar om att reparera tarmcellernas skyddsbarriär för att behandla sjukdomen.

Major advances in IVF labs in the last few decades

Since the introduction of in vitro fertilisation several decades ago, many developments have been made in the field, and the main part of that development has t...

Lonza

Metabolon

22 miljarder – så mycket kostar det att utveckla ett nytt läkemedel

Den genomsnittliga kostnaden för Big Pharma att ta ett läkemedel hela vägen från upptäckt till lansering var i fjol 2,23 miljarder dollar, motsvarande en bra bi...

Medical device quality assurance

Recordings from ZEISS Quality Innovation Days.

QPS Netherlands B.V

Pfizer’s Paxlovid is being tested against post-COVID in a major Swedish study

In a new study conducted at the Karolinska University Hospital, Pfizer’s COVID drug, Paxlovid, is now being tested in patients with post-COVID. The study is one...

CROs in drug development: "We use our expertise to speed up the process

Consultancy firms have become an increasingly important part of drug development. “It’s a trend and a business model that works, and we see no indication that i...

Uppsalabolag prisas för utveckling av snabbtest för antibiotikaresistens

Uppsalabolaget Sysmex Astrego prisas för sitt antibiotikakänslighetstest. Företaget tilldelades under onsdagen the Longitude Prize och får ta emot 8 miljoner pund.

Double up for Korbinian Löbmann

This year, Korbinian Löbmann will moderate the New Updates in Drug Formulation & Bioavailability meeting in Copenhagen for the fifth time. Furthermore, he will ...

“Photon counting in computed tomography is the holy grail”

Erik Fredenberg, a researcher in physics at KTH and GE, is working to implement photon-counting CT in clinics. To shorten lead times and reduce the radiation do...

The first drugs to slow down Alzheimer’s – but what does it mean for patients?

New treatments for early Alzheimer’s are bringing hope to thousands of patients and their families. The question is, who will get the treatment, how will the ri...

Forterro Sweden

Marie Gårdmark: Big data evidence generation drives change in the EU regulatory system

Rapid developments in technology have led to the possibility for the generation and analysis of vast volumes of data. Will the availability of big data lead to ...

Rapid development in blood analysis – “Sweden is leading the race”

Thousands of analytical tests using just one single drop of blood. What was revealed as a hoax just a few years ago is now a reality, according to KTH professor...

Study: Vaccination linked to lower risk of post-COVID

The risk of developing post-COVID after a COVID infection was reduced in vaccinated people, according to a new study from the University of Gothenburg.

Elicera develops CAR-T against solid tumours – may become the first in the world

Today, there are five EU-approved CAR-T therapies, all focused on different types of blood cancer, but no one has yet succeeded in making the method work agains...

Astra Zeneca lägger ut miljonbelopp i Ryssland – ”Varken acceptabelt eller försvarligt”

Svensk-brittiska Astra Zeneca har spenderat mångmiljonbelopp i Ryssland efter krigsutbrottet. Det handlar bland annat om bidrag, donationer, genomföranden av st...

Elypta awarded one million USD from the Star Trek creator’s foundation

Swedish company Elypta, which develops methods for early cancer detection, has been awarded one million USD from an unexpected source: a foundation set up in me...

Founder of Bioarctic, Lars Lannfelt, is honoured: “I want to create something for the future”

It´s like a scientist’s dream: to be the world’s first with a drug that genuinely affects one of our major diseases. Lars Lannfelt and his company Bioarctic hav...

Scale Up Your Image Analysis

ZEISS arivis Hub for accelerated analysis and faster results.